{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:21:09Z","timestamp":1784676069795,"version":"3.55.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Global Napi Pharmaceutical Company","award":["600"],"award-info":[{"award-number":["600"]}]},{"name":"Global Napi Pharmaceutical Company","award":["000 LE"],"award-info":[{"award-number":["000 LE"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dual antiplatelet therapy with aspirin and a thienopyridine is used to prevent thrombotic complications of acute coronary syndrome (ACS) and percutaneous coronary interventions (PCI). Ticagrelor is an oral, reversible inhibitor of the adenosine diphosphate receptor P2Y12 with a faster onset and more potent platelet inhibition than clopidogrel. A study was needed to evaluate the efficacy and safety of generic ticagrelor in Egyptian patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This multicenter study included 830 patients aged above 40\u00a0years and diagnosed with ACS, with or without ST segment elevation during the preceding 6\u00a0months. They received generic ticagrelor (Thrombolinta, Global Napi Pharmaceutical Company, Egypt) (180\u00a0mg loading dose, 90\u00a0mg twice daily thereafter), added to aspirin 75\u2013100\u00a0mg daily. The mean age of our study population was 57.5 (8.3) years and 38.3% were females. Hypertension, diabetes mellitus, dyslipidemia and previous coronary revascularization were present in 70.7%, 59.2%, 80.7% and 31% of the patients, respectively, and 42.5% were current smokers. The qualifying event was unstable angina, non-ST segment elevation myocardial infarction and ST segment elevation myocardial infarction in 54%, 21.8% and 24.2% of the patients, respectively. At 6\u00a0months, the primary efficacy end point\u2014a composite of cardiovascular death, myocardial infarction and stroke\u2014occurred in 3.4% of patients, while the secondary efficacy endpoint\u2014a composite of the primary efficacy endpoints with the addition of hospitalization for unstable angina and urgent revascularization\u2014occurred in 15.3%. Cardiovascular death occurred in 1.2% of the patients, myocardial infarction in 0.8%, stroke in 1.3%, hospitalization for UA in 8.1% and urgent revascularization in 3.9%. TIMI major bleeding occurred in 1.2% of patients, intracranial hemorrhage in 0.2% and TIMI minor bleeding in 13.3%. No significant difference was found between patients who underwent PCI at baseline and those who were treated conservatively regarding the primary (14 patients in each group, <jats:italic>P<\/jats:italic>\u2009=\u20090.931) and secondary (62 vs. 65 patients, <jats:italic>P<\/jats:italic>\u2009=\u20090.946) efficacy endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients who had an ACS during the 6\u00a0months preceding enrollment, treatment with generic ticagrelor led to a low rate of cardiovascular death, myocardial infarction and stroke with a minor increase in the risk of major bleeding.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-022-00290-w","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T08:05:06Z","timestamp":1655798706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insights from Egyptian ticagrelor study in patients who presented with acute coronary syndrome (ETS in ACS)"],"prefix":"10.1186","volume":"74","author":[{"given":"Hesham S.","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam","family":"Kandil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam","family":"Mahrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna M.","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"issue":"24","key":"290_CR1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMRA071014","volume":"357","author":"G Dav\u00ec","year":"2007","unstructured":"Dav\u00ec G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357(24):2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMRA071014","journal-title":"N Engl J Med"},{"issue":"9678","key":"290_CR2","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"R Collins","year":"2009","unstructured":"Collins R, Peto R, Hennekens C et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England) 373(9678):1849\u20131860. https:\/\/doi.org\/10.1016\/S0140-6736(09)60503-1","journal-title":"Lancet (London, England)"},{"issue":"11","key":"290_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMOA0904327\/SUPPL_FILE\/NEJM_WALLENTIN_1045SA1.PDF","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045\u20131057. https:\/\/doi.org\/10.1056\/NEJMOA0904327\/SUPPL_FILE\/NEJM_WALLENTIN_1045SA1.PDF","journal-title":"N Engl J Med"},{"issue":"3","key":"290_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/EURHEARTJ\/EHV320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet J-P et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267\u2013315. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHV320","journal-title":"Eur Heart J"},{"issue":"3","key":"290_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/EURHEARTJ\/EHY462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K, Alpert JS, Jaffe AS et al (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40(3):237\u2013269. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHY462","journal-title":"Eur Heart J"},{"issue":"23","key":"290_CR6","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123(23):2736\u20132747. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449","journal-title":"Circulation"},{"issue":"19","key":"290_CR7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMOA1500857\/SUPPL_FILE\/NEJMOA1500857_DISCLOSURES.PDF","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of Ticagrelor in patients with prior myocardial infarction. N Engl J Med 372(19):1791\u20131800. https:\/\/doi.org\/10.1056\/NEJMOA1500857\/SUPPL_FILE\/NEJMOA1500857_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"11","key":"290_CR8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.amjcard.2011.07.015","volume":"108","author":"RF Storey","year":"2011","unstructured":"Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Lim ST, Cannon CP, Katus HA, Wallentin L (2011) Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and patient outcomes [PLATO] pulmonary function substudy). Am J Cardiol 108(11):1542\u20131546. https:\/\/doi.org\/10.1016\/j.amjcard.2011.07.015","journal-title":"Am J Cardiol"},{"issue":"19","key":"290_CR9","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/J.JACC.2007.07.053","volume":"50","author":"CP Cannon","year":"2007","unstructured":"Cannon CP, Husted S, Harrington RA et al (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome. Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50(19):1844\u20131851. https:\/\/doi.org\/10.1016\/J.JACC.2007.07.053","journal-title":"J Am Coll Cardiol"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-022-00290-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-022-00290-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-022-00290-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T08:08:42Z","timestamp":1655798922000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-022-00290-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1186\/s43044-022-00290-w","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research involved human subjects and was performed in accordance with the Declaration of Helsinki and approved by Local Ethical Committee at Ain Shams University (12\/9\/2020). Consent to participate: An informed written consent to participate in the study was provided by all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}